GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Iran Daru (XTEH:IRDR1) » Definitions » Debt-to-Equity

Iran Daru (XTEH:IRDR1) Debt-to-Equity : 0.00 (As of . 20)


View and export this data going back to 1990. Start your Free Trial

What is Iran Daru Debt-to-Equity?

Iran Daru's Short-Term Debt & Capital Lease Obligation for the quarter that ended in . 20 was IRR0.00 Mil. Iran Daru's Long-Term Debt & Capital Lease Obligation for the quarter that ended in . 20 was IRR0.00 Mil. Iran Daru's Total Stockholders Equity for the quarter that ended in . 20 was IRR0.00 Mil.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Iran Daru's Debt-to-Equity or its related term are showing as below:

XTEH:IRDR1's Debt-to-Equity is not ranked *
in the Drug Manufacturers industry.
Industry Median: 0.3
* Ranked among companies with meaningful Debt-to-Equity only.

Iran Daru Debt-to-Equity Historical Data

The historical data trend for Iran Daru's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Iran Daru Debt-to-Equity Chart

Iran Daru Annual Data
Trend
Debt-to-Equity

Iran Daru Semi-Annual Data
Debt-to-Equity

Competitive Comparison of Iran Daru's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Iran Daru's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Iran Daru's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Iran Daru's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Iran Daru's Debt-to-Equity falls into.



Iran Daru Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Iran Daru's Debt to Equity Ratio for the fiscal year that ended in . 20 is calculated as

Iran Daru's Debt to Equity Ratio for the quarter that ended in . 20 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Iran Daru  (XTEH:IRDR1) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Iran Daru Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Iran Daru's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Iran Daru (XTEH:IRDR1) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
Ayatollah Saeedi Highway, End Of Kermani Street, Moallem Boulevard, Tehran, IRN, 1371658111
Iran Daru is a pharmaceutical company based in Iran. It manufactures and sells pharmaceutical products for antibiotics, cardiovascular agents, and local anesthetic agents. The company manufactures products in three main dosage form categories namely solid, semi-solid, and liquid including tablets, capsules, pellets, sachets, gels, creams, ointments (sterile and non-sterile), spray solutions, and syrups. Products offered by Iran Daru include Diclofenac Potassium, Biotin 5 mg, Tetracycline, Folic acid, Meloxicam, Acetaminophen and Caffeine, and Levocetirizine dihydrochloride, among others. It also exports its products to other countries.

Iran Daru (XTEH:IRDR1) Headlines

No Headlines